机器学习预测儿童免疫性血小板减少症患者对利妥昔单抗的应答:迈向个体化医疗之路
本研究分析了北京儿童医院2020至2023年间156例儿童免疫性血小板减少症(ITP)患者的数据,构建机器学习模型预测利妥昔单抗的初始应答。四种模型中多层感知器预测准确率最高。SHAP分析显示,抗核抗体滴度、甲状腺球蛋白抗体、糖皮质激素应答和出血严重程度为显著正向预测因子,而甲状腺过氧化物酶抗体、CD3+CD4+IL-17+T细胞及利妥昔单抗治疗前病程与治疗应答负相关。该模型有望优化治疗策略并改善患者结局。
要点
- 基于156例儿童ITP患者数据构建机器学习模型预测利妥昔单抗初始应答。
- 多层感知器模型在四种评估模型中预测准确率最高。
- 抗核抗体滴度、甲状腺球蛋白抗体、糖皮质激素应答和出血严重程度为显著正向预测因子。
核心结论
- 该机器学习模型可用于预测儿童ITP患者对利妥昔单抗的应答,有望优化治疗策略并改善患者结局。
研究设计与样本
- 研究分析了北京儿童医院2020至2023年间接受利妥昔单抗治疗的156例儿童ITP患者数据,并识别出25个关键预测特征。
主要发现
- 在四种评估的机器学习模型中,多层感知器模型表现出最高的预测准确率。
- SHAP分析显示,抗核抗体滴度、甲状腺球蛋白抗体、糖皮质激素应答和出血严重程度为显著正向预测因子。
- 甲状腺过氧化物酶抗体、CD3+CD4+IL-17+T细胞及利妥昔单抗治疗前病程与治疗应答负相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by decreased platelet counts and increased bleeding risk. Although paediatric ITP often resolves spontaneously, some children do not respond to first-line treatments, thus requiring rituximab as a second-line therapy to reduce bleeding risks and corticosteroid exposure. Currently, there is no reliable method to predict the efficacy of rituximab. Our study aimed to develop a machine learning (ML) model to predict the initial response to rituximab in these patients. We analysed data from 156 paediatric ITP patients treated at Beijing Children's Hospital between 2020 and 2023 and identified 25 key predictive features. Among the four evaluated ML models, the multilayer perceptron model exhibited the highest predictive accuracy. SHapley Additive exPlanations analysis revealed that antinuclear antibody titre, thyroglobulin antibody, corticosteroid response and bleeding severity were significant positive predictors, while thyroid peroxidase antibody, CD3+ CD4+ IL-17+ T cells and the duration of disease before rituximab treatment were negatively associated with treatment responses. This ML model could be used to predict rituximab responses in paediatric ITP, which is expected to optimize treatment strategies and improve patient outcomes.
引用
- Ma J, Cui C, Ouyang J, et al. Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care. Br J Haematol. 2025. PMID: 40665492. doi:10.1111/bjh.20251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。